
Global venture capital partnership investing in data, technology and analytics companies, backed by RELX Group

Stem cell and drug discovery research company supplying iPSC tools, human tissue testing and clinical services

Researchers working with stem cells, teams testing drugs before trials and groups running clinical studies make up the customer base of ReproCELL, which sells products and services for each stage. Its stated purpose is to help bench research turn into treatments, and its site arranges the work by customer: cell therapy developers, stem cell researchers, preclinical drug developers and clinical drug developers.
The research side centres on induced pluripotent stem cells (iPSCs). The company offers ready-to-use research iPSC lines, a custom iPSC reprogramming service, differentiated iPSCs with related reagents, and pluripotent stem cell culture media. It describes the work as running from donor sourcing and footprint-free reprogramming to precise gene editing, using its StemRNA technology, with quality control meant to keep the cell lines reproducible.
For cell therapy developers, ReproCELL describes integrated, regulatory-aligned workflows that start with finding donors, move through deriving and editing cells, and end in manufacturing under GMP rules. Clinical StemRNA iPSCs and GMP master cell banking are named among the services, aimed at shortening the route from discovery to the clinic.
Biopta is the brand for preclinical and drug discovery contract research. It uses human tissue to model how people respond to a drug, which the company says helps close the gap between animal studies and clinical trials. It offers a drug discovery assay catalogue and bioengineered 3D tissue models, as well as biospecimens, genomic analysis and laboratory expertise for work such as identifying biomarkers or validating targets.
For clinical trials the company says it coordinates, processes, tests and analyses fresh human biospecimens from study setup to final data delivery. It cites more than 25 years of project and logistical management experience and GLP, GCLP and ISO-compliant systems running around the clock.
Other lines in the range include growth factors, cytokines, antibodies and staining kits, Alvetex three-dimensional cell culture systems, EZSPHERE multiwell plates, ABLE Biott bioreactors, and goods sold under the Bioserve and Stemgent names.
ReproCELL is a research company that supplies products and services for stem cell science, preclinical drug testing and clinical development. Scientists around the world use its offerings to move laboratory findings towards therapies.
Cell therapy developers, stem cell researchers, preclinical and clinical drug developers, and diagnostic developers.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about ReproCELL.
Similar listings buyers compare against this one.

Global venture capital partnership investing in data, technology and analytics companies, backed by RELX Group

Crypto and blockchain investor backing multi-stage Web3 companies worldwide, part of CTH

Early-stage venture firm backing pre-seed and seed founders in Canada and the US

Biotechnology investment firm that creates and funds therapeutics companies, including via its BioImpact arm

Technology investor backing fast-growing, high-margin companies in fintech and other large markets

Seed-stage venture fund for founders in the Pacific Northwest, run by former founders

A global venture capital firm investing from early stage through growth in technology founders

European technology growth capital firm providing expansion and buyout funding to fast-growing small and medium-sized companies
Everything here links back to the same verified catalogue. Pick your next stop.